Do Preoperative Bilirubin Levels Affect Recovery and Hospital Stay After Sedation Anesthesia?
Launched by NAIME YALÇIN · Feb 25, 2025
Trial Information
Current as of July 02, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Bilirubin is a lipid-soluble substance produced as the end product of heme metabolism in mammals. It easily crosses cell membranes, including the blood-brain barrier (BBB), and has been reported to have both neuroprotective and neurotoxic effects. Most bilirubin binds to albumin, but unbound bilirubin crosses the BBB, binds to nerve cells, and exhibits cytotoxic effects. Neurological symptoms resulting from hyperbilirubinemia are common in neonates, but decrease after BBB maturation. However, patients may be susceptible/vulnerable to neurological complications as a result of liver cirrhosis...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years of age and older
- • ASA I-IV status
- • Both genders
- • To be operated under sedation anesthesia for ERCP procedure
- Exclusion Criteria:
- • age \<18
- • pregnancy
- • lack of informed consent (such as patients with mental retardation or
- • language problems)
- • history of allergy to any agent used during sedation
- • baseline O2 saturation \<90%
- • baseline systolic blood pressure \<90 mmHg
- • procedure performed under general anesthesia
About Naime Yalçın
Naime Yalçın is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a strong focus on innovative therapeutic solutions, Naime Yalçın oversees the planning, execution, and management of clinical trials across various therapeutic areas. The organization prioritizes regulatory compliance, ethical standards, and the integrity of data, ensuring that all trial activities are conducted with the utmost professionalism. Through collaboration with healthcare professionals and research institutions, Naime Yalçın aims to facilitate the development of safe and effective treatments that meet the needs of patients and contribute to the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İstanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported